Seeking Alpha

Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer’s Disease

New LEQEMBI Companion™ program launched to expand helpful resources for patients throughout the treatment journey, including Nurse Educators who can provide patients with injection training, and an ...
Hosted on MSN

FDA delays decision on Biogen’s Alzheimer’s injection to August

FDA review extended: Regulators added three months to review Biogen’s Leqembi Iqlik, setting a new decision date of August 24, 2026. Reason for delay: The FDA requested more data, classifying it as a ...

Biogen Inc.: Update on FDA Priority Review of LEQEMBI IQLIK (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer's Disease

Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period ...
Hosted on MSN

FDA delays decision on Biogen’s Leqembi Alzheimer’s injection to August

Review extended: The FDA pushed back its decision on Leqembi IQLIK by three months to August 24, 2026, after requesting more information from Biogen and Eisai. Reason for delay: The agency classified ...
KXAN

Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease

New LEQEMBI Companion TM program launched to expand helpful resources for patients throughout the treatment journey, including Nurse Educators who can provide patients with injection training, and an ...